- Home
- VINP vs ORIC Comparison
VINP vs ORIC Comparison
Compare VINP & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VINP | ORIC |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 702.6M | 1.2B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VINP | ORIC |
|---|---|---|
| Price | $10.34 | $12.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $14.00 | ★ $20.00 |
| AVG Volume (30 Days) | 77.7K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 5.95% | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.80 | N/A |
| Revenue Next Year | $13.97 | N/A |
| P/E Ratio | $24.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.66 | $3.90 |
| 52 Week High | $13.61 | $14.93 |
Technical Indicators
Market Signals| Indicator | VINP | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 28.79 | 49.72 |
| Support Level | $9.25 | $11.37 |
| Resistance Level | $10.87 | $12.12 |
| Average True Range (ATR) | 0.60 | 0.84 |
| MACD | -0.14 | -0.21 |
| Stochastic Oscillator | 9.43 | 36.05 |
Price Performance
Historical ComparisonAbout VINP Vinci Partners Investments Ltd.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.